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Background: To determine the clinical value of apparent diffusion coefficient (ADC) measurement by diffusion
weighted magnetic resonance imaging (DW-MRI) in differentiating renal tumors.
Methods: Electronic databases were searched using combinations of keywords and free words relating to renal
tumor, ADC and DW-MRI. Based on carefully selected inclusion and exclusion criteria, relevant case–control studies
were identified and the related clinical data was acquired. Statistical analyses were performed using STATA 12.0
(Stata Corporation, College station, TX).
Results: Sixteen case–control studies were ultimately included in the present meta-analysis. These 16 high quality
studies contained a combined total of 438 normal renal tissues and 832 renal tumor lesions (597 malignant and
235 benign). The results revealed that ADC values of malignant renal tumor tissues were markedly lower than
normal renal tissues and benign renal tumor tissues. ADC values of benign renal tumor tissues were also
significantly lower than normal renal tissue.
Conclusions: ADC measurement by DW-MRI provided clinically useful information on the internal structure of
renal tumors and could be an important radiographic index for differentiation of malignant renal tumors from
benign renal tumors.
Keywords: Diffusion weighted magnetic resonance imaging, Apparent diffusion coefficient, Renal tumors,
Differentiation, B value, Renal malignant tissues, Benign renal tumor tissues, Meta-analysisBackground
Kidney cancers in adults involve malignant tumors
originating from renal pelvis and renal parenchyma [1].
It is the deadliest of urological malignancies, with an es-
timated 58,000 Americans diagnosed in 2010 alone, and
is associated with a relatively poor five-year survival rate
of 65% [2]. Clinically, nearly 80-90% of kidney cancers
are classified as renal cell carcinoma (RCC), which arises
in the renal parenchyma [3,4]. RCC accounts for 2-3%
of all malignancies in adults, and is the seventh most
frequent cancer in men and the ninth most frequent
cancer in women [5]. Although the overall survival rate
is more than 60% over 5 years, approximately 30% of* Correspondence: liuailian704@126.com
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unless otherwise stated.RCC patients diagnosed with a localized disease at pres-
entation will progress to develop metastatic disease [6].
Etiologically, the established risk factors for RCC include
genetic component (such as the von-Hippel Lindau gene
mutations), race (African Americans have higher inci-
dence), gender (higher risk in males), obesity, smoking
and hypertension [1,7]. Recently, owing to the rampant
use of abdominal imaging techniques in clinical diagnos-
tics, such as ultrasonography, computed tomography
and magnetic resonance imaging, the proportion of
small and incidental renal tumors have increased sharply
[5]. The best chance to cure RCC is through nephrec-
tomy, and given that RCC is refractive to chemotherapy
and radiation therapy, early diagnosis is currently the
best approach to increasing patient survival [8]. Certain
lesions may imitate tumors on diagnostic imaging, even
though lesions are histologically composed of normal ors is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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entiation between benign and malignant renal tumors is crit-
ical for therapy planning and to distinguish surgical from
non-surgical tumors [10]. Despite the technological advances
in diagnostic imaging, the possibility of surgical discovery of
benign pathology remains high in suspected cases of renal
malignancy [9].
Diffusion-weighted magnetic resonance imaging (DW-
MRI) measures the Brownian motion of water molecules
in biological tissues [11]. It is sensitive to random mo-
tion of endogenous water molecules within the tissue
environment, and the technique is particularly suited to
both clinical and basic science applications [12]. DW-
MRI provides critical information on biophysical proper-
ties of tissues, such as cell organization, cell density,
microstructure and microcirculation, via detecting the
motion of water molecules within a voxel without the
need for administration of contrast agents [13]. The
apparent diffusion coefficient (ADC) is a quantitative
parameter computed from DW-MRI data to assess the
extent of diffusion of water molecules [14]. Increased
cellular density limits water diffusion into the interstitial
space and ADC values are inversely proportional to cell
density, thus ADC values are useful to obtain clinically
useful correlations in a disease setting [10]. For instance,
ADC values provide a non-invasive method to predict
the histological subtype and nuclear grade of RCC [15].
Recently, application of DW-MRI in oncology imaging
has improved the differential diagnosis of benign and
malignant tumors in brain, liver, breast, prostate and
several female pelvic organs [16-19]. However, few re-
ports discuss the clinical value of DW-MRI in differenti-
ating between renal tumors [20,21]. To address this issue,
we performed a comprehensive meta-analysis to examine
published data for assessment of the clinical value of




A systematic search of electronic databases, including
PubMed, Wiley, EBSCO, SpringerLink, Web of Science,
Ovid, China National Knowledge Infrastructure (CNKI),
Wanfang database and VIP Information databases, was
performed (last search in October 2014), according to
the PRISMA guidelines (http://prisma-statement.org/, as
shown in Additional file 1). Random combinations of fol-
lowing keywords was utilized for the search: (“diffusion
magnetic resonance imaging” or “diffusion MRI” or “diffu-
sion weighted MRI” or “diffusion weighted imaging” or
“DWI” or “WB-DWI” or “DMRI” or “diffusion ”), (“kidney
neoplasms” or “renal neoplasms” or “cancer of kidney” or
“kidney cancers” or “renal cancer” or “cancer of the kid-
ney” or “renal adenocarcinoma” or “renal tumor” or “renalcarcinoma” or “malignant tumor of kidney”). The title and
abstract of studies retrieved from the search were exam-
ined manually to exclude inappropriate publication, and
cross-references of all remaining literature on the study
topic were inspected for additional relevant studies.
Eligibility criteria
The studies selected in this meta-analysis were clinical
case–control studies reporting differentiation of renal
tumors using ADC measurement by DW-MRI. The
eligible studies met the following inclusion criteria: (1)
included study subjects were patients with renal tumors
and healthy controls; (2) included papers provided
complete data on age, country, language, ethnicity, gen-
der, number of lesions, pathological types, types of MRI
machines, b-value, and ADC value; (3) if multiple studies
included overlapping data, only the study with latest or
largest data was included.
Studies were excluded if (1) the research topic was un-
related to the differential diagnosis of renal tumors using
ADC measurement by DW-MRI; (2) no comparisons
between healthy controls and malignant tumors, or
between benign tumor and malignant tumor; (3) studies
published in languages other than Chinese or English;
(4) repeat publications; (5) incomplete data.
Data extraction and quality evaluation
Data from qualified studies were collected by two inde-
pendent investigators, using a predefined data collection
table. The predefined tables were designed to extract all
relevant data, figures and tables from the texts, including
country, first author, year, language, ethnicity, study de-
sign, patient number, age, gender, and pathological types.
Quality evaluation of included studies was performed
by more than 2 investigators by methodological index for
non-Randomized studies (MINORS) criteria [22]. MI-
NORS, a verified scoring tool for non-randomized studies,
include a 12-item assessment. The score of each item
ranges from 0 to 2 with an ideal total score of 24 for com-
parative studies and a score of 16 for non-comparative
studies. The specific 12 criteria were as follows: whether
the stated aim was clear (MINORS01), whether the inclu-
sion of patients was consecutive (MINORS02), whether
the prospective data was collected (MINORS03), whether
the endpoints for aim were appropriate (MINORS04),
whether assessment of endpoint was unbiased (MI-
NORS05), whether the follow-up period was appropriate
(MINORS06), whether the loss to follow-up was less than
5% (MINORS07), whether study size was prospectively
calculated (MINORS08), whether the control group was
adequate (MINORS09), whether the groups were contem-
porary (MINORS10), whether the baseline of groups was
equivalent (MINORS11), whether the statistical analyses
were adequate (MINORS12).
Liu et al. BMC Cancer  (2015) 15:292 Page 3 of 11Statistical analysis
STATA 12.0 software (Stata Corporation, College
Station, TX, USA) was used for statistical analysis in
the present meta-analysis. The correlation between ADC
measurement by DW-MRI and the differentiation of
renal tumors was calculated by standard mean difference
(SMD) with 95% confidence intervals (CI), applying
a random-effects model or a fixed-effects model. The
Z test was performed to determine the significance
of pooled SMDs. Heterogeneity across studies was
evaluated by Cochran’s Q-statistic (a P value < 0.05 was
considered significant) and I2 test (0%, no heterogeneity;Figure 1 Flow chart of literature selection process.100%, maximal heterogeneity) [23]. A random or fixed-
effects model was used on the basis of the heterogeneity
analysis. When significant heterogeneity existed among
studies (P < 0.05 or I2 > 50%), a random-effects model
was used, otherwise, a fixed-effects model was used
[24,25]. Sensitivity analysis was performed by deleting
single study one by one, to evaluate the effects of single
study on the overall result. The publication bias which
assessed the reliability of result was evaluated by
contour-enhanced funnel plot and Egger test [26,27].
Univariate and multivariate meta-regression analyses
were applied to examine the source of heterogeneity,
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correct and verify the results [28].
Results
Study selection
A total of 316 studies were retrieved after the search of
electronic databases. Next, the articles were reviewed,
resulting in 288 eligible articles after removing duplicates.
After reading the full texts, we excluded 272 articles for
the following reasons: the studies were not human studies
(n = 22), were letters, reviews or meta-analyses (n = 4),
were not related to research topics (n = 177), were not
case–control studies (n = 21), were not relevant to kidney
neoplasms (n = 26), were not relevant to MRI or ADC
value (n = 21), and contained incomplete data in articles
(n = 1). Sixteen articles [10,14,21,29-41] (14 in English and
2 in Chinese) satisfied the inclusion and exclusion criteria
and were selected for data extraction and data analysis.
Figure 1 shows the literature selection processes. All in-
cluded studies were published between 2004 and 2014.
Among the 16 studies, study subjects in 9 trials were
Asians, 6 trials were performed in Caucasians and 1 trial
was conducted in African population. Based on the coun-
try of publication, 4 studies were from China, 3 fromFigure 2 The quality scores of included studies by methodological index fTurkey, 1 from US, 2 from Japan, 2 from Italy, and 1 each
from Austria, France, Germany, Egypt. This meta-analysis
included 438 normal healthy renal tissues and 832 renal
tumor lesions (597 malignant and 235 benign). The three
types of MRI machines used were Siemens, GE and Phi-
lips, and the b-values were 500 s/mm2, 600 s/mm2, 800 s/
mm2, 1000 s/mm2, 500/1000 s/mm2 and 400/800 s/mm2.
The quality score and the baseline characteristics of
included studies are shown in Figure 2 and Table 1,
respectively.
Results of meta-analysis
The heterogeneity test revealed that there was het-
erogeneity across studies that compared ADC values
between different tissues (normal renal tissues vs.
malignant renal tumor tissues: P < 0.001, I2 = 94.4%;
malignant renal tumor tissues vs. benign renal tumor
tissues: P < 0.001, I2 = 96.1%; normal renal tissues vs.
benign renal tumor tissues: P < 0.001, I2 = 97.3%), thus a
random-effects model was applied in all cases. As shown
in Figure 3, the present meta-analysis revealed that the
ADC values of malignant renal tumor tissues were signifi-
cantly lower than normal renal tissues (SMD = 2.40,
95% CI = 1.72 ~ 3.08, P < 0.001) and benign renal tumoror non-randomized studies.
Table 1 Baseline characteristics of the sixteen included studies
First author Year Country Ethnicity Age (years) Gender (F/M) MRI machine type b value (s/mm2) b value (s/mm2)
Sevcenco S [21] 2014 Austria Caucasians 64(21–85) - Siemens 500/1000 71
Zhang YL [29] 2013 China Asians 52 41/23 GE 500 121
Agnello F [30] 2013 France Caucasians 61.6(27–88) 19/16 Philips 1000 47
Yu X [31] 2012 China Asians 53 (30–81) 93/44 GE 800 274
Rheinheimer S [32] 2012 Germany Caucasians 60.4 (36–83) 37/19 Siemens 800 54
Inci E [33] 2012 Turkey Asians 53.5 74/61 Siemens 500/1000 88
Zhang YL-a [34] 2011 China Asians 7-79 - Philips 500 97
Zhang YL-c [34] 2011 China Asians 7-79 - Philips 800 97
Zhang YL-d [34] 2011 China Asians 7-79 - Philips 1000 97
Zhang J [35] 2011 China Asians 30-76 - GE 800 40
Tanaka H[14] 2011 Japan Asians 57 (38 ~ 78) 21/14 Philips 800 82
Razek AA [10] 2011 Egypt Africans 5-67 24/28 GE 800 54
Doganay S-b [36] 2011 Turkey Asians 53(1–76) 25/33 GE 600 117
Doganay S-d [36] 2011 Turkey Asians 53(1–76) 25/33 GE 1000 117
Kim S [37] 2009 USA Caucasians - - Siemens 400/800 64
Kilickesmez O [38] 2009 Turkey Asians 45.6 46/56 Siemens 500/1000 66
Manenti G [39] 2008 Italy Caucasians 58.8(30–85) 22/15 Philips 500 37
Yoshikawa T [40] 2006 Japan Asians 61.9 122/78 Philips 600 20
Squillaci E [41] 2004 Italy Caucasians 55.7(29–85) 20/18 Philips 500 38
F = female; M = male; MRI = magnetic resonance imaging; GE = general electric; a, b = 500; b, b = 600; c, b = 800; d, b =1000.
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ADC values of benign renal tumor tissues were also
significantly lower than normal renal tissues (SMD= 2.84,
95% CI = 1.30 ~ 4.39, P < 0.001).
Subgroup analyses
Subgroup analysis based on the types of MRI equipment
indicated that there was significant difference between
ADC values of normal renal tissue vs. malignant renal
tumor tissue, normal renal tissue vs. benign renal tumor
tissue, and benign renal tumor tissue and malignant
renal tumor tissue when the equipment used was
Siemens and Philips (P < 0.05). Significant differences
also existed in ADC values of normal renal tissue vs.
malignant renal tumor tissue, when the MRI equipment
was from GE (P < 0.05).
Additionally, subgroup analysis based on b-value
found that when b = 500 s/mm2, 600 s/mm2, 800 s/mm2,
500/1000 s/mm2, there was significant difference be-
tween ADC values of normal renal tissue and malignant
renal tumor tissue (P < 0.01), while at b = 1000 s/mm2,
no significant difference was observed (P > 0.05). When
b = 500 s/mm2, 500/1000 s/mm2, there was significant
difference between ADC values of normal renal
tissue and benign renal tumor tissue (P < 0.05), while
at b = 600 s/mm2, 800 s/mm2, 1000 s/mm2, no
marked difference was detected (P > 0.05). Specific
results of subgroup analyses on ADC values ofDW-MRI in differentiation of renal tumors are present in
Table 2.
Sensitivity analysis and publication bias
All studies related to comparisons between normal renal
tissue and malignant renal tumor tissue, and the com-
parisons between malignant renal tumor tissue and be-
nign renal tumor tissue showed no evident effect on the
pooled SMD. The Contour-enhanced funnel plots, of
studies investigating the comparisons between normal
renal tissue and malignant renal tumor tissue as well as
the comparisons between benign renal tumor tissue and
malignant renal tumor tissue, indicated there was
publication bias (P > 0.05) which was further con-
firmed by the Egger test (P > 0.05). There was no
publication bias across studies that explored compari-
sons between normal tumor tissue and benign renal
tumor tissue (P < 0.01), which was also confirmed by
the Egger test (P = 0.002) (as shown in Figure 4).
Regression analysis
Univariate meta-regression analysis and multivariate
meta-regression analysis were conducted. Univariate
meta-regression analysis showed that, in studies that car-
ried out the comparisons between normal renal tissue
and malignant renal tumor tissue, publication year, sample
size, country, ethnicity, types of MRI mechanisms and
b-value had no correlation with heterogeneity (P > 0.05),
Figure 3 Forest plots of apparent diffusion coefficient values of diffusion-weighted magnetic resonance imaging in differentiation of renal tumors
(A: comparison of ADC values between normal renal tissues and malignant renal tumor tissues; B: comparison of ADC values between benign and
malignant renal tumor tissues; C: comparison of ADC values between normal renal tissues and benign renal tumor tissues).
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Table 2 Standard mean difference of subgroup analyses on apparent diffusion coefficient values of diffusion-weighted
magnetic resonance imaging in differential diagnosis of renal tumors
Normal VS. Malignant Benign VS. Malignant Normal VS. Benign
SMD 95% CI P SMD 95% CI P SMD 95% CI P
Ethnicity:
Asians 2.54 1.71-3.37 <0.001 0.22 −1.45-0.77 0.016 2.84 1.30-4.39 < 0.001
Caucasians 1.85 1.24-2.45 < 0.001 −1.07 0.43-2.62 0.013 - - -
Africans - - - −1.00 −1.74-(−0.26) 0.008 - - -
Machine type:
GE 1.73 0.94-2.52 < 0.001 −0.05 −0.21-0.30 0.713 0.74 −0.55-2.04 0.259
SIEMENS 3.34 1.50-5.17 < 0.001 −0.58 −0.91-(−0.26) < 0.001 4.21 3.14-5.28 < 0.001
PHILIPS 2.52 1.07-3.98 0.001 2.21 1.90-2.53 < 0.001 4.15 1.56-6.73 0.002
b value:
500 2.08 1.11-3.05 < 0.001 1.85 1.48-2.22 < 0.001 3.36 1.22-5.49 0.002
600 0.94 0.47-1.41 < 0.001 −0.27 −0.70-0.17 0.233 −0.10 −0.53-0.34 0.664
800 2.22 0.97-3.48 0.001 1.43 0.95-1.90 < 0.001 2.99 −1.82-7.80 0.223
1000 2.55 −0.37-5.48 0.087 0.59 0.25-0.93 0.001 3.11 −2.87-9.08 0.308
400/800 - - - −1.37 −1.93-(−0.82) < 0.001 - - -
500/1000 4.19 3.45-4.93 < 0.001 −0.18 −0.58-0.22 0.375 4.21 3.14-5.28 < 0.001
SMD = standard mean difference; 95% CI = 95% confidence intervals; GE = general electric.
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In studies that investigated comparisons between benign
renal tumor tissue and malignant renal tumor tissue,
publication year, sample size, ethnicity, b-value (P > 0.05)
were not related to heterogeneity, and country, language
and types of MRI machines correlate with heterogeneity
(P < 0.05). In studies that carried out the comparisons be-
tween normal renal tissue and benign renal tumor tissue,
country might be associated with heterogeneity (P < 0.05),
but not publication year, sample size, publication year, and
sample sizes (P > 0.05).
The multivariate meta-regression analysis revealed
that, as shown in Table 3 and Table 4, in studies that
compared normal renal tissue and malignant renal
tumor tissue or between benign renal tumor tissue and
malignant renal tumor tissue, publication year, sample
size, country, language, ethnicity, types of MRI equip-
ment and b value of MRI were not the main sources
of heterogeneity. In studies that carried out the compari-
sons of normal renal tissue and benign renal tumor
tissue, country was the main source of heterogeneity,
but not the publication year, sample size, types of MRI
machines or b-value (Table 5).
Discussion
The diagnostic value of DW-MRI as a stand-alone
approach in detailed characterization of renal tumors is
controversial. Some clinicians consider DW-MRI as an
effective diagnostic tool to differentiate benign from
malignant tumors in multiple organs [16-19], but othersare skeptical about the physics and the dynamics of
DW-MRI in a tumor setting [20,21]. We investigated the
clinical significance of DW-MRI using a meta-analysis
based approach.
DW-MRI is a noninvasive imaging technique that is
sensitive to thermally driven water molecule motion in-
side the body [42]. This random motion is frequently
represented with a monoexponential model with ADC
as its parameter [43]. ADC is a quantitative tool for mul-
tiple clinical applications and is important in differentiat-
ing benign from malignant lesions, evaluating tumor
aggressiveness, performing early assessment of tumor
response to therapy [44]. RCCs are classically classified
into several representative subtypes including clear cell,
chromophobe, and papillary RCCs on the basis of histo-
logical appearance and abnormal presence of genetic
patterns, and clinical courses [7]. Fortunately, with the
advantages of DW-MRI in differentiating RCCs from
normal renal parenchyma, ADC value could be helpful
in characterizing RCC subtypes [20,31,45]. Accurate esti-
mation of ADC is pivotal in precise diagnosis, evalu-
ation, and monitoring of human pathologies [44]. In this
meta-analysis, we found that the ADC values of malig-
nant renal tumor tissues were markedly lower than nor-
mal renal tissues and benign renal tumor tissues.
Further, the ADC values of benign renal tumor tissues
were also significantly lower than normal renal tissues.
The images acquired by DW-MRI are constructed via
quantifying the diffusion of water molecules in tissues and
DWI uses differences in water motion to discriminate
Figure 4 Sensitivity analyses and funnel plots of apparent diffusion coefficient values of diffusion-weighted magnetic resonance imaging in differentiation
of renal tumors (A: Sensitivity analysis comparing normal renal tissues and malignant renal tumor tissues; B: Sensitivity analysis comparing benign and
malignant renal tumor tissues; C: Sensitivity analysis comparing normal renal tissues and benign renal tumor tissues; D: Publication bias comparing
normal renal tissues and malignant renal tumor tissues; E: Publication bias comparing benign and malignant renal tumor tissues; F: Publication bias
comparing normal renal tissues and benign renal tumor tissues).
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Table 3 Multivariate regression analyses of apparent




Coefficient SE t P (Adjusted) 95% CI
LL UL
Year 0.107 0.422 0.25 1 −0.925 1.138
Sample Size 0.005 0.112 0.45 0.994 −0.223 0.032
Country 0.18 0.54 0.33 0.998 −1.14 1.5
Language 2.372 2.667 0.89 0.878 −4.154 8.898
Ethnicity −0.353 1.501 −0.24 1 −4.025 3.32
Machine type −0.056 0.792 −0.07 1 −1.993 1.88
b value −0.338 0.454 −0.74 0.941 −1.449 0.774
SE = standard error; 95% CI = 95% confidence intervals; LL = lower limit;
UL = upper limit.
Table 5 Meta-regression analyses of apparent diffusion




Coefficient SE t P (Adjusted) 95% CI
LL UL
Year −3.385 0.97 −3.49 0.114 −7.558 0.789
Sample Size −0.364 0.07 −5.18 0.149 −0.667 −0.061
Country −1.785 0.259 −6.89 0.026 −2.901 −0.67
Machine type −5.645 1.444 −3.91 0.092 −11.856 0.567
b value −0.383 0.263 1.46 0.492 −0.746 1.513
SE = standard error; 95% CI = 95% confidence intervals; LL = lower limit;
UL = upper limit.
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lignant lesions, diffusion is often restricted due to higher
cellularity, tissue disorganization and decreased extracellu-
lar space, generating higher signal intensity on DW-MRI
[48]. Histologically, RCC is composed of large tumor cells
with abundant clear cytoplasm and very narrow intercellu-
lar space, which restrict water movement and resulted
in low ADC values [49]. Therefore, ADC measurements
using DW-MRI has been used as a surrogate marker for
cellularity, to evaluate successful treatment and cell kill
[50]. Additionally, RCC tumors are unique due to the
presence of hemosiderin deposits, which help in distin-
guishing RCC tumors from other tumors [51]. A manu-
script by Childs et al. revealed that in-phase signal loss,
likely correlating with hemosiderin deposits, is observed in
approximately 21% of renal masses and 42% of papillary
RCC, suggesting that the paramagnetic effect of hemo-
siderin is responsible for the losses of in-phase signal
intensity and intravoxel dephasing induced by T2
RCC, frequently observed in RCC tumors [52]. This
susceptibility-induced intravoxel dephasing is predom-
inant in DW-MRI of RCC tumors because largerTable 4 Meta-regression analyses of apparent diffusion




Coefficient SE t P (Adjusted) 95% CI
LL UL
Year −0.424 0.358 −1.18 0.771 −1.204 0.356
Sample Size −0.003 0.025 −0.12 1 −0.058 0.052
Country −0.461 0.315 −1.47 0.598 −1.147 0.224
Language 1.857 1.721 1.08 0.827 −1.895 5.608
Ethnicity 0.159 0.752 0.21 1 −1.48 1.8
Machine type 0.433 0.74 0.59 0.988 −1.18 2.047
b value 0.038 0.332 0.11 1 −0.686 0.761
SE = standard error; 95% CI = 95% confidence intervals; LL = lower limit;
UL = upper limit.intravoxel dephasing degree causes greater signal in-
tensity loss [53]. Therefore, hemosiderin within renal
tumors may lead to limited sensitivity of DW-MRI in
diagnosis of malignant renal tumors, as observed in sev-
eral studies. Moreover, when intravenous contrast cannot
be administered, for instance in patients with end-stage
renal disease, and heterogeneity between T1 and T2 is
very important, and one MRI sequence alone cannot be
relied upon to differentiate between benign and malignant
tumors.
We also conducted subgroup analyses by types of MRI
machines and b-value. Subgroup analysis by types of
MRI suggested that Siemens and Philips MRI were more
broadly applicable, owing to their clinical efficiency,
compared to GE. Lastly, subgroup analysis based on b-
value, showed that MRI machines at different b-values
might differ in discriminating the renal tumors.
Certain limitations existed in the study design and
should be considered. First, the number of patients in
several included studies was relatively small, and the
number of patients with renal lesions was also relatively
small, which might reduce the reliability of the conclu-
sions. Second, our meta-analysis was based on published
studies, which tend to report positive or significant re-
sults, while studies with negative or insignificant results
are not available for analysis. This might have led to
a publication bias, which may have overestimated the
results. In addition, this meta-analysis was restricted to
studies published in English or Chinese, which might
have introduced bias. Moreover, different RCC subtypes
in the selected studies may have statistically significant
differences in ADC values, and might influence the final
results of this meta-analysis to some extent.
Conclusion
In conclusion, in spite of the limitations of our meta-
analysis, the evidence supports that ADC measurement
by DW-MRI is a useful tool to measure the properties of
the internal structure of tumors, and could be an important
radiographic index for the differentiation of renal tumors.
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